Journal of Pain & Palliative Care Pharmacotherapy最新文献_第5页

Intravenous Zoledronic Acid for Bone Pain Relief in Cancer Patients with Bone Metastasis Receiving Low Dose Opioids and Nsaids: A Randomized Controlled Study. 静脉注射唑来膦酸缓解接受低剂量阿片类药物和非甾体抗炎药治疗的骨转移癌患者骨痛：一项随机对照研究。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-13 DOI: 10.1080/15360288.2026.2718825

Attiqa Choudhary, Zahida Aziz, Naine Badrala, Neha Sharma

{"title":"Intravenous Zoledronic Acid for Bone Pain Relief in Cancer Patients with Bone Metastasis Receiving Low Dose Opioids and Nsaids: A Randomized Controlled Study.","authors":"Attiqa Choudhary, Zahida Aziz, Naine Badrala, Neha Sharma","doi":"10.1080/15360288.2026.2718825","DOIUrl":"10.1080/15360288.2026.2718825","url":null,"abstract":"Bone is a frequent site of metastasis, particularly in breast, lung, prostate, and renal cancers. Skeletal metastases lead to severe pain, fractures, hypercalcemia, and reduced quality of life. Zoledronic acid(ZA), a potent intravenous bisphosphonate, inhibits osteoclast-mediated bone resorption and may reduce metastatic bone pain. This study assessed the efficacy and safety of intravenous zoledronic acid in relieving bone pain in patients with bone metastases receiving standard analgesics. In this randomized prospective controlled study, out of 120, 70 adults aged 30-70 years with confirmed bone metastases and visual analog score of >4 who completed the follow up were enrolled. Patients were randomized into two groups (35 each), Group Z received ZA 4 mg intravenously (every 4 wk) along with low-dose morphine 5 mg every 4 h and tablet etoricoxib 60 mg twice daily and Group P received tab morphine 5 mg every 4 h and tab etoricoxib 60 mg twice daily. All patients received calcium and vitamin D supplementation. Weekly assessments included BPI scores, skeletal-related events, and adverse effects. Patients receiving intravenous ZA demonstrated significantly greater reductions in pain severity and fewer skeletal-related events than Group P (p < 0.05). No serious drug-related adverse effects were noted.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.3,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

My Mother's Pain Was Always a Number. 我母亲的痛苦总是一个数字。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-11 DOI: 10.1080/15360288.2026.2713512

Yuliana Dyah Rahmawati, Pramana

引用次数: 0

The Hours the Medicine Took Away. 药物带走的时间。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-06 DOI: 10.1080/15360288.2026.2713523

Pramana, Adi Inggit Handoko

引用次数: 0

The Hours Between Doses. 剂量间隔的时间。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-03 DOI: 10.1080/15360288.2026.2713519

Pramana, Mira Adita Widianti

引用次数: 0

When the Pump Went Silent. 当水泵静音时。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-01 DOI: 10.1080/15360288.2026.2713511

Vangipuram Shankar

引用次数: 0

Stock-Out. 库存中断。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-08-01 DOI: 10.1080/15360288.2026.2713515

Ghio Vani Debrian Soares

引用次数: 0

Efficacy of Oral Melatonin Versus Oral Olanzapine in Improving Sleep in Cancer Patients with Insomnia: Prospective Comparative Study. 口服褪黑素与口服奥氮平改善癌症失眠患者睡眠的疗效：前瞻性比较研究。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-07-31 DOI: 10.1080/15360288.2026.2707225

Surendra Kumar Pingoliya, Deepak Kumar Garg, Shaheer Abdulla, Aastha Bhaskar

{"title":"Efficacy of Oral Melatonin Versus Oral Olanzapine in Improving Sleep in Cancer Patients with Insomnia: Prospective Comparative Study.","authors":"Surendra Kumar Pingoliya, Deepak Kumar Garg, Shaheer Abdulla, Aastha Bhaskar","doi":"10.1080/15360288.2026.2707225","DOIUrl":"https://doi.org/10.1080/15360288.2026.2707225","url":null,"abstract":"Sleep deprivation is a common concern for cancer patients. It has proven difficult to determine severity of sleep disturbances in a cancer group. Patients may fail to mention insomnia because they assume it is a common and temporary reaction to a cancer diagnosis or treatment, a condition that is frequently overlooked in cancer management. This prospective, double-blind, randomized comparative trial evaluated the efficacy and safety of oral melatonin (3 mg/day) versus oral olanzapine (5 mg/day) in 60 advanced cancer patients with insomnia over four weeks. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) and Athens Insomnia Scale (AIS) at baseline, 2nd wk, and 4th wk. Both groups demonstrated significant, time-dependent improvement in sleep parameters (p < 0.001). Melatonin showed statistically significant superiority over olanzapine in PSQI scores at week four and overall AIS scores across all time points; however, melatonin exhibited a more favorable adverse effect profile, while olanzapine was associated with somnolence, akathisia, and weight gain. Both agents are effective for cancer-related insomnia symptoms, with melatonin offering a superior tolerability advantage in the palliative setting. Larger placebo-controlled trials with objective sleep measures are warranted to confirm these findings.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.3,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paresthesia After Suzetrigine: A Second Report and Case Comparison. 舒三嗪后感觉异常：第二次报告与病例比较。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-07-29 DOI: 10.1080/15360288.2026.2709499

Daniel Adams, Dmitri Souza

引用次数: 0

Centralized Pain Diagnoses in Older Adults With and Without Cancer. 有和没有癌症的老年人集中疼痛诊断。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-07-25 DOI: 10.1080/15360288.2026.2701348

Madison N Irwin, Vincent Marshall, N Lynn Henry, Karen Farris, Michael A Smith

{"title":"Centralized Pain Diagnoses in Older Adults With and Without Cancer.","authors":"Madison N Irwin, Vincent Marshall, N Lynn Henry, Karen Farris, Michael A Smith","doi":"10.1080/15360288.2026.2701348","DOIUrl":"10.1080/15360288.2026.2701348","url":null,"abstract":"Chronic pain is highly prevalent in older adult cancer survivors, but the prevalence of nociplastic pain is ill-defined. This is important because nociplastic pain responds poorly to opioids, the cornerstone of cancer pain management. Moreover, older adults face high risk of respiratory depression, falls, and mortality from opioids. Given these risks, a better understanding of nociplastic pain prevalence is needed. This was a cross-sectional analysis study at a large, academic medical center. Patients ≥65 years of age with at least one outpatient visit between November 1, 2015 and December 23, 2021 were included. The primary outcome was the proportion of older adults, with and without cancer, with a chronic overlapping pain condition (COPC) diagnosis (a type of nociplastic pain). There were 320,727 older adults included and 15.5% carried at least one COPC diagnosis. Those with COPCs were more likely to be female, younger, and have a higher Elixhauser Comorbidity Index. Black Americans were less likely to carry a COPC diagnosis. The incidence rate of COPCs was 1.0333 times higher in older adults with cancer (95% CI [1.014, 1.053], p = 0.001). One in six older adults had a COPC diagnosis. Those with cancer were more likely to carry a COPC diagnosis than their peers without.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.3,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148592235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When Pain Learns the Name of a Child. 当痛苦知道一个孩子的名字。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-07-24 DOI: 10.1080/15360288.2026.2705433

Mukhamad Zulianto

引用次数: 0